MedTrace Logo

Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma

NCT07767630 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-08-21

No results posted yet for this study

Summary

Fractionated dosing of \[211At\]MABG Radiotherapy in Relapsed/Refractory Neuroblastoma

Conditions

  • Neuroblastoma (NB)

Interventions

DRUG

[211At]MABG

Fractionated Dose

Sponsors & Collaborators

  • Sichuan University

    lead OTHER

Principal Investigators

  • Rong TIAN, MD · West China Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-21
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07767630 on ClinicalTrials.gov